protein S (beta) pseudogeneGenealiases: PROS2 · PROSP
Q-omics provides the consensus-scored PROS2P profile across patient tissues and cancer cell-line models. PROS2P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PROS2P is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, PROS2P RNA expression shows 6,963 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where PROS2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROS2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROS2P survival associations across molecular data types. PROS2P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROS2P RNA expression–survival associations across cancer types. High PROS2P expression shows unfavorable associations in LGG, SKCM, CHOL and THYM, but favorable associations in KIRC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for PROS2P RNA expression.
This table summarizes PROS2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PROS2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROS2P shows lower tumor expression in KICH, LIHC, BRCA and LUAD and higher tumor expression in THCA and COAD. The THCA box plot shows higher PROS2P RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p < 0.001).
This table shows molecular features associated with PROS2P in patient tissues and cancer cell lines. In patient samples, PROS2P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
